Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis.
Vaccinia virus (VACV), the prototype poxvirus, encodes numerous proteins that modulate the host response to infection. Two such proteins, B14 and A52, act inside infected cells to inhibit activation of NF-kappaB, thereby blocking the production of pro-inflammatory cytokines. We have solved the cryst...
Main Authors: | Graham, S, Bahar, M, Cooray, S, Chen, R, Whalen, D, Abrescia, N, Alderton, D, Owens, R, Stuart, D, Smith, G, Grimes, J |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Public Library of Science
2008
|
פריטים דומים
-
Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis.
מאת: Stephen C Graham, et al.
יצא לאור: (2008-08-01) -
Mapping the IkappaB kinase beta (IKKbeta)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKbeta-mediated activation of nuclear factor kappaB.
מאת: Benfield, C, et al.
יצא לאור: (2011) -
Nuclear Factor-kappaB in Autoimmunity: Man and Mouse
מאת: Bahar Miraghazadeh, et al.
יצא לאור: (2018-04-01) -
NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts.
מאת: Smith, C, et al.
יצא לאור: (2001) -
Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.
מאת: Andreakos, E, et al.
יצא לאור: (2006)